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OBJECTIVES: The purpose was to estimate the EI of VM
in the United States from payer and societal perspectives.
METHODS: The EI of VM was estimated by applying
the cost and probability estimates of events in a decision
analytic framework (DAF). DAF development and prob-
ability of events were obtained from an expert panel. Di-
rect medical costs were estimated by charge data ob-
tained from the 1996 Pennsylvania Medicaid database
and the Drug Topics Red Book. Indirect costs were ob-
tained in terms of activity restricted days (ARDs) as esti-
mated by the panel. ARDs were defined as the average
number of days patients with VM missed school/work or
normal activities. Monte Carlo simulations were used to
generate the distribution of charges for estimating the EI
of VM on a per patient basis. The per patient EI was then
extrapolated to the US population. Sensitivity analyses
(one-way) were conducted by varying the probability val-
ues at the dominant nodes, nodes with high-cost, and
nodes with the largest ranges.
RESULTS: An episode of VM poses direct medical costs
to payers ranging from $4500 to $5700 in adult patients
and $5000 to $5300 in pediatric patients. Similarly, an
episode of VM poses an average of 5.6 to 7.5 ARDs.
These results were stable across the sensitivity parameters
tested.
CONCLUSIONS: Management of VM imposes a sizable
economic burden from both the payer and societal per-
spectives. Based on a conservatively estimated 250,000
annual cases of VM in the United States, the economic
burden to payers in terms of direct costs exceeds $1 bil-
lion per year. The additional economic burden in terms
of indirect costs to society would approximate 1.5 mil-
lion ARDs.
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Prior estimates of the cost of epilepsy have been based on
expert panels and decision-analysis models, but not on
national data.
OBJECTIVES: To estimate annual medical resource use
and payer costs of inpatient and outpatient medical care
related to epilepsy.
METHODS: Using three sources of national survey data
from 1992 to 1996—1) the Healthcare Cost and Utiliza-
tion Project Nationwide Inpatient Sample (NIS), 2) the
National Ambulatory Medical Care Survey (NAMCS),
and 3) the National Hospital Ambulatory Medical Care
Survey (NHAMCS)—we identified all inpatient admis-
sions and outpatient encounters with a primary ICD-9-
CM diagnosis code, and alternatively, any diagnosis code,
of epilepsy (345.1–345.9) or convulsions (780.3). We
then assigned an allowed charge to each encounter by
matching it to an encounter in Medicare’s Standard Ana-
lytic File (SAF). Annual rates of medical resource use and
payer costs were then estimated, by diagnosis and payer
type.
RESULTS: The annual payer cost of inpatient and outpa-
tient care with a primary diagnosis of epilepsy or convul-
sions was approximately $4.8 billion. Medicare accounted
for 35% of these costs followed by private insurers/HMOs
(28%) and Medicaid (27%). Encounters with a primary
diagnosis of convulsions accounted for 73% of costs,
while those coded as epilepsy accounted for the remaining
27%. Annual cost of care with any diagnosis code for epi-
lepsy or convulsions was $22 billion.
CONCLUSION: Even without accounting for medica-
tions, the costs of epilepsy appear higher than previously
estimated. This analysis provides a national estimate of
the inpatient and outpatient costs of epilepsy.
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Colon cancer is a common cause of malignancy in men
and women. The incidence has been increasing over the
past several decades. Fecal occult blood testing has been
shown in several randomized controlled studies to reduce
the rate of colorectal cancer. The US Preventive Task
Force has recommended universal screening after the age
of 50. More than 150,000 new cases of colon cancer are
diagnosed each year. The mortality rate continues to be
greater than 50% in these diagnosed cases. Various fecal
occult blood tests (FOBT) used in screening colorectal
cancer have reduced mortality by 15–30%.
OBJECTIVE: The purpose of this study was to assess the
effectiveness of fecal occult blood testing in reducing the
mortality rate from colorectal cancer as part of a man-
aged care program. The suggested number of patients
needed for screening to prevent one death from colon can-
cer is 1374 for 5 years. The cost of FOBT is relatively in-
